Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer?
Authors:
- 1 February 2007
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 112 (5) , 281-289
Abstract
Steroid-resistant sarcoidosis has conventionally been treated with various drugs, including methotrexate, azathioprine, cyclophosphamide, cyclosporine, antimalarial drugs and thalidomide, with variable success. There is a compelling need for more efficient and safer alternatives to these agents. Several lines of evidence suggest a critical role of TNF-α (tumour necrosis factor-α) in the initiation and organization of sarcoid granulomas. Inhibition of TNF-α with monoclonal antibodies has therefore received attention as a potential treatment option in therapy-resistant sarcoidosis. A number of case reports and small case series describe successful treatment of refractory disease with infliximab. Preliminary evidence from an RCT (randomized controlled trial) with infliximab in pulmonary sarcoidosis suggests a modest improvement in functional and radiological parameters. In contrast, the results with etanercept have been disappointing, perhaps related to differences in the mechanism of TNF-α blockade. The experience with adalimumab in sarcoidosis is too limited to draw conclusions. An open-label study and an RCT evaluating the efficacy of adalimumab in sarcoidosis with pulmonary and cutaneous involvement respectively, have been initiated. Although TNF-α antagonists appear relatively safe, especially when compared with conventional agents, caution is warranted in view of the increased incidence of tuberculosis, which may be a particular diagnostic challenge in patients with sarcoidosis. Pending publication of the RCTs, the use of TNF-α blockade in sarcoidosis should remain in the realm of experimental treatment.Keywords
This publication has 62 references indexed in Scilit:
- Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modesRheumatology, 2006
- Ulcerative cutaneous sarcoidosis responding to adalimumabJournal of the American Academy of Dermatology, 2005
- TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritisClinical Science, 2005
- B cells in rheumatoid arthritis: from hypothesis to the clinicRheumatology, 2005
- Pulmonary sarcoidosisAllergy, 2005
- Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patientsAnnals of the Rheumatic Diseases, 2004
- Successful tumor necrosis factor α blockade treatment in therapy‐resistant sarcoidosisArthritis & Rheumatism, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- POLYMORPHISMS AT POSITION −308 IN THE PROMOTER REGION OF THE TNF-α AND IN THE FIRST INTRON OF THE TNF-β GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-α RELEASE IN SARCOIDOSISCytokine, 1999
- Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanningEuropean Respiratory Journal, 1994